Three Main SCFAs Mitigate Lung Inflammation and Tissue Remodeling Nlrp3-Dependent in Murine HDM-Induced Neutrophilic Asthma

Tagé, Barbara S. S.; Gonzatti, Michelangelo B.; Vieira, Rodolfo P.; Keller, Alexandre C.; Bortoluci, Karina R.; Aimbire, Flávio

doi:10.1007/s10753-024-01983-x

Cited by 4 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intestinal microbiota is closely related to the pathogenesis of asthma (Barcik et al, 2020 ). Intestinal microbiota can regulate the immune function of the body by increasing the level of SCFAs, and then affect the occurrence and development of asthma (Tagé et al, 2024 ). However, due to the close and complex relationship between intestinal microbiota and asthma, the specific regulation mechanism of intestinal microbiota participating in immune tolerance is not completely clear, so it needs to be further elucidated (Tan et al, 2023 ).…”

Section: Possible Mechanisms Of Gut Microbiota In Respiratory Diseasesmentioning

confidence: 99%

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Sun,

Lu,

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Preclinical evidence has firmly established a bidirectional interaction among the lung, gut, and gut microbiome. There are many complex communication pathways between the lung and intestine, which affect each other's balance. Some metabolites produced by intestinal microorganisms, intestinal immune cells, and immune factors enter lung tissue through blood circulation and participate in lung immune function. Altered gut–lung–microbiome interactions have been identified in rodent models and humans of several lung diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease, lung cancer, asthma, etc. Emerging evidence suggests that microbial therapies can prevent and treat respiratory diseases, but it is unclear whether this association is a simple correlation with the pathological mechanisms of the disease or the result of causation. In this review, we summarize the complex and critical link between the gut microbiota and the lung, as well as the influence and mechanism of the gut microbiota on respiratory diseases, and discuss the role of interventions such as prebiotics and fecal bacteria transplantation on respiratory diseases. To provide a reference for the rational design of large-scale clinical studies, the direct application of microbial therapy to respiratory-related diseases can reduce the incidence and severity of diseases and accompanying complications.

show abstract

Section: Possible Mechanisms Of Gut Microbiota In Respiratory Diseasesmentioning

confidence: 99%

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Sun,

Lu,

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…SCFAs have been demonstrated to protect against allergic diseases in mouse models. A study found that SCFAs can mitigate inflammatory cytokines and markers of tissue remodeling in house dust mite (HDM)-induced neutrophilic murine asthma [30]. Meanwhile, it has been reported that SCFA-producing bacteria, such as Bifidobacterium, Lactobacillus and Bacteroides, may regulate inflammatory responses and reduce the risk of asthma [31].…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiota-Derived Tryptophan Metabolites Alleviate Allergic Asthma Inflammation in Ovalbumin-Induced Mice

Wang,

He,

Dang

et al. 2024

Foods

View full text Add to dashboard Cite

Asthma is a prevalent respiratory disease. The present study is designed to determine whether gut microbiota-derived tryptophan metabolites alleviate allergic asthma inflammation in ovalbumin (OVA)-induced mice and explore the effect and potential mechanism therein. Asthma model mice were constructed by OVA treatment, and kynurenine (KYN), indole-3-lactic acid (ILA), in-dole-3-carbaldehyde (I3C), and indole acetic acid (IAA) were administered by intraperitoneal injection. The percent survival, weight and asthma symptom score of mice were recorded. The total immunoglobulin E and OVA-specific (s)IgE in the serum and the inflammatory cytokines in the bronchoalveolar lavage fluid (BALF) were detected by the corresponding ELISA kits. The composition of the gut microbiota and tryptophan-targeted metabolism in mouse feces were analyzed using 16S rRNA gene sequencing and targeted metabolomics, respectively. The four tryptophan metabolites improved the percent survival, weight and asthma symptoms of mice, and reduced the inflammatory cells in lung tissues, especially I3C. I3C and IAA significantly (p < 0.05) downregulated the levels of OVA-IgE and inflammatory cytokines. KYN was observed to help restore gut microbiota diversity. Additionally, I3C, KYN, and ILA increased the relative abundance of Anaeroplasma, Akkermansia, and Ruminococcus_1, respectively, which were connected with tryptophan metabolic pathways. IAA also enhanced capability of tryptophan metabolism by the gut microbiota, restoring tryptophan metabolism and increasing production of other tryptophan metabolites. These findings suggest that tryptophan metabolites may modulate asthma through the gut microbiota, offering potential benefits for clinical asthma management.

show abstract

The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications

Zhou,

Wang,

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Three Main SCFAs Mitigate Lung Inflammation and Tissue Remodeling Nlrp3-Dependent in Murine HDM-Induced Neutrophilic Asthma

Cited by 4 publications

References 58 publications

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Gut Microbiota-Derived Tryptophan Metabolites Alleviate Allergic Asthma Inflammation in Ovalbumin-Induced Mice

The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications

Contact Info

Product

Resources

About